ATH-399A

N/A

Report date: 2025/03/31 16:54:20

Base Information

Drug NameATH-399A
Drug Alias NameATH-399AHL192HL-192DWP-307399
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionNuclear receptor subfamily 4 group A member 2 activators
TargetsNuclear receptor subfamily 4 group A member 2
Therapy Area/IndicationsRestless Legs SyndromeNeurodegenerative DiseasesParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNurrOn Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNurrOn Pharmaceuticals IncHanAll Biopharma Co LtdDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsRestless Legs SyndromeNeurodegenerative DiseasesParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A